Sector News

Trump’s U.K. visit sparks plans for mass protests—and dinner invites for GSK, J&J CEOs: FT

July 5, 2018
Life sciences

As officials on both sides of the Atlantic prepare for President Donald Trump’s visit to the U.K. next week—and amid plans for mass protests while he’s there—some Big Pharma CEOs have been invited to a black-tie dinner with Trump and Prime Minister Theresa May, according to the Financial Times.

Among the slate of multinational executives invited are Johnson & Johnson CEO Alex Gorsky and GlaxoSmithKline CEO Emma Walmsley, the newspaper reports. The location of the dinner has not been released, but some sources told the FT they’re expecting it to take place in Blenheim Palace, a lavish estate near Oxford and the birthplace of Winston Churchill.

But some business leaders say they’re skeptical the gathering will go forward, according to the report.

Mass protests are expected during Trump’s “working visit,” according to numerous publications. The president’s official appearance will come right on the heels of a NATO summit and right before a meeting between Trump and Russian president Vladimir Putin.

Representatives for GSK and J&J didn’t immediately respond to requests for more information.

In the U.S., Trump’s administration recently unveiled a plan to lower drug costs by stepping up pricing negotiations and competition—from new generics and brands alike—as well as providing incentives for lower list prices and helping to lower patients’ out-of-pocket costs.

Meanwhile, Brexit continues to grow closer in the U.K., and drugmakers are reportedly deploying plans to mitigate potential supply issues ahead of the March 2019 separation deadline. Merck & Co., for instance, reportedly plans to stockpile a six-month supply of drugs to hedge against shipping complications.

As part of the Brexit separation, the European Medicines Agency is relocating its headquarters to Amsterdam, taking with it 900 jobs and an estimated economic impact of $1 billion.

By Eric Sagonowsky

Source: Fierce Pharma

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend